Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 5/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3327579 | 0.87 | PTPN2 (0.51) | ADORA3ADORA2AADORA1NPC1RAB9A | |
| SCHEMBL3347092 | 0.82 | NPC1 (0.47) | NPC1RAB9AS1PR1 | |
| SCHEMBL3362758 | 0.80 | ABL1 (0.52) | NPY5RADORA3ADORA2AADORA1GSK3B | |
| SCHEMBL3343347 | 0.77 | JAK2 (0.48) | — | |
| SCHEMBL10192549 | 0.76 | HTT (0.50) | NPC1RAB9A | |
| SCHEMBL3367312 | 0.75 | NPC1 (0.43) | NPC1RAB9AS1PR1 | |
| SCHEMBL14108403 | 0.75 | MLLT1 (0.47) | NPC1RAB9AS1PR1 | |
| Hydrochloric Acid SCHEMBL28847292 | 0.73 | MLLT1 (0.46) | NPC1RAB9AS1PR1 | |
| SCHEMBL3333820 | 0.73 | MAPT (0.46) | ADORA3ADORA2AADORA1GSK3BNPC1 | |
| SCHEMBL3341742 | 0.73 | MAPK1 (0.46) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653125-B2 | Cyclohexane derivative having NPY Y5 receptor antagonism | SHIONOGI CO., LTD. (JP) | 2014-02-18 | — | — | US | disclosed |
| EP-2404896-A1 | CYCLOHEXANE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISM | Shionogi&Co., Ltd. (JP) | 2012-01-11 | — | — | EP | disclosed |
| US-20120004227-A1 | CYCLOHEXANE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISM | SHIONOGI & CO., LTD. (JP) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004227-A1 | CYCLOHEXANE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISM | NPY5R, NPY1R, NPY2R | NPY5R 1/4885ADORA3 604/4885ADORA2A 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.